60-Year-Old Gave Himself Early 20th Century Psychosis After He Went To ChatGPT For Diet Advice
The man, who remained anonymous in the case study, told doctors he had eliminated sodium chloride, commonly known as table salt, from his diet after reading about its negative health effects. He said he could only find sources telling him how to reduce salt, but not eliminate it completely.
Inspired by his nutrition studies in college, the man decided to completely eliminate sodium chloride from his diet as a personal experiment, with consultation from Chat GPT, researchers wrote. He maintained multiple dietary restrictions and even distilled his own water at home.
'For 3 months, he had replaced sodium chloride with sodium bromide obtained from the internet after consultation with ChatGPT, in which he had read that chloride can be swapped with bromide, though likely for other purposes, such as cleaning,' the case study read.
While excess sodium can raise blood pressure and increase the risk of health issues, it is still necessary to consume a healthy amount of it.
The man, who had no psychiatric history, eventually ended up at the hospital, worried that his neighbor was poisoning him. He told doctors he was very thirsty, but paranoid about the water he was offered.
'In the first 24 hours of admission, he expressed increasing paranoia and auditory and visual hallucinations, which, after attempting to escape, resulted in an involuntary psychiatric hold for grave disability,' the study read.
Doctors concluded that the man was suffering from bromism, or bromide toxicity, a condition that is rare today but was more common in the early 20th century. The research noted that bromide was found in several over-the-counter medicines back then and contributed to up to 8% of bromism-related psychiatric admissions at that time.
The hospital treated the man for psychosis and discharged him weeks later. His case highlights the potential pitfalls of using AI to seek medical tips.
Dr. Margaret Lozovatsky, a pediatrician, warned last year that AI often misses crucial context.
'Even if the source is appropriate, when some of these tools are trying to combine everything into a summary, it's often missing context clues, meaning it might forget a negative,' she told the American Medical Association. 'So, it might forget the word 'not' and give you the opposite advice.'
Related...
ChatGPT Was Asked To List Everyone Trump Has Called 'A Low-IQ Individual' — And It's Pretty Racist
Elon Musk Soft Launches 'NSFW' AI Companion A Week After Chatbot Goes On Antisemitic Tirade
These Tragic AI Fails Are Proof That You Can't Fully Rely On ChatGPT To Plan Your Trip
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
15 minutes ago
- Medscape
Blood Cell Patterns Predict Poor Venetoclax Response
TOPLINE: Erythroid-predominant myelodysplastic neoplasms (EP MDS) (18%) exhibit unique genomic features with frequent TP53 mutations and distinct survival patterns. These cases show poor outcomes with venetoclax therapy due to BCL-XL dependence rather than BCL2, suggesting the need for alternative treatment strategies. METHODOLOGY: Researchers evaluated 371 consecutive patients with newly diagnosed MDS presenting between December 2016 and January 2023, excluding those with chronic myelomonocytic leukemia and acute erythroid leukemia. A separate cohort of 112 consecutive patients with higher-risk MDS and increased blasts > 5% received hypomethylating agent plus venetoclax therapy between April 2017 and November 2023. Patients with insufficient, poor, or inadequate bone marrow samples were excluded to avoid hemodilution confounding effects. EP MDS were defined as those with > 50% normoblasts plus pronormoblasts as a percentage of total bone marrow nucleated cells, while multi-hit TP53-mutated status was defined as having 2 distinct TP53 mutations, concomitant TP53 mutation and deletion of chromosome 17p/TP53, or TP53 variant allele frequency of > 50%. TAKEAWAY: EP MDS (n = 67; 18%) showed higher frequencies of TP53 mutations (multi-hit TP53: 36% vs 17%; P = .004), BCOR mutations (12% vs 4%; P = .015), and WT1 mutations (9% vs 2%; P = .011) than non-EP cases (n = 304; 82%). Three distinct genetic subgroups were identified in EP cases with significantly different survival outcomes: TP53 mutant (median survival, 11.4 months), splicing mutant (not reached), and not otherwise specifiable (19.5 months) (P < .001). Among hypomethylating agent-venetoclax treated patients, EP cases showed higher leukemic transformation rates (32% vs 12%; P = .040) and worse survival (8.3 months vs not reached; P = .041). Immunohistochemistry analysis revealed significantly higher BCL-XL-positive cell frequencies in EP than in non-EP cases (62.5% vs 10%; P = .013), with lower BCL2-positive cell frequencies (5% vs 30%; P = .052). IN PRACTICE: 'Overall, our findings provide a detailed characterization of EP MDS and demonstrate its distinct molecular and clinical profile compared to NEP MDS. Notably, we demonstrate that although EP MDS comprises distinct genomic subsets with diverging clinical behavior, a group of these patients experience poor outcomes with currently available therapies. Our work supports the development of alternative therapeutic strategies in high-risk EP MDS cases. It sets the basis for recognizing the importance of dynamically assessing erythroid populations in MDS and developing future clinical trials evaluating the activity of BCL-XL inhibitors in this group of patients,' the authors of the study wrote. SOURCE: This study was led by Alexandre Bazinet, MD, Sanam Loghavi, MD, and Guillermo Montalban-Bravo, MD, at The University of Texas MD Anderson Cancer Center in Houston. It was published online in Leukemia. LIMITATIONS: The researchers acknowledged several limitations, including that results were from a single-center study. The low frequency of EP MDS (18% of all cases) limited their ability to definitively identify distinct genomic subgroups. Limited sample availability affected transcriptional characterization and immunohistochemical profiling of large numbers of patients within each EP group. The authors noted that increased BCL-XL expression findings require future validation, and functional studies are needed to confirm whether increased BCL-XL RNA and protein expression translates into BCL-XL dependence. Given the high incidence of TP53 mutations in EP MDS, further studies are needed to determine if poor outcomes with venetoclax-based therapy are driven by TP53 mutations or erythroid-differentiation bias. DISCLOSURES: This study was supported by the University of Texas MD Anderson Cancer Center Support Grant CA016672, the University of Texas MD Anderson Myelodysplastic Syndromes/Acute Myeloid Leukemia Moon Shot, and the Translational Molecular Pathology-Immunoprofiling lab MoonShots Platform. Sanam Loghavi, MD, disclosed ties with Amgen, Astellas, and multiple other pharmaceutical companies. Hagop Kantarjian, MD, reported relationships with various pharmaceutical companies including AbbVie, Agios, and Amgen. Guillermo Garcia-Manero, MD, disclosed ties with Celgene Corporation, Astex, and Amphivena. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Business Insider
16 minutes ago
- Business Insider
Mark Cuban says the US has got to keep investing in research if it wants to have a chance of beating China at AI
"Shark Tank" star Mark Cuban says the US can beat China at AI if it continues "investing in research of all kinds as a country." "The IP we create domestically is what the frontier models can buy or invest in to define their differentiation and advance forward," Cuban wrote on X in response to a post by David Sacks, the White House's AI and crypto czar, on the state of the AI race. When asked about his X post, Cuban told Business Insider that American research is "important, not just because of the outcome of the research itself, but its value to American frontier AI models" like ChatGPT and Gemini. Cuban said that any unique intellectual property produced can be "licensed to the models, for a fee, to be included in their training." This would not only offset research costs but also make the models more valuable, he added. "The quality and depth of the research we do in this country can help us stay ahead of China and other countries in the AI race," Cuban told Business Insider. "We need our Ph.D.s, our scientists, our experts, to stay here and contribute to society, and their IP to make American AI models the global leaders," he added. Since taking office in January, President Donald Trump's administration has been culling research grants for universities and research institutions like the National Institutes of Health (NIH). Please help BI improve our Business, Tech, and Innovation coverage by sharing a bit about your role — it will help us tailor content that matters most to people like you. What is your job title? (1 of 2) Entry level position Project manager Management Senior management Executive management Student Self-employed Retired Other Continue By providing this information, you agree that Business Insider may use this data to improve your site experience and for targeted advertising. By continuing you agree that you accept the Terms of Service and Privacy Policy . Researchers and scientists told Business Insider's Ayelet Sheffey in April that the cuts could stifle innovation and result in brain drain. "It absolutely endangers the United States' position as the global leader in medical research. And for that, we will pay," Peter Lurie, a recipient of an NIH grant terminated in March, told Sheffey. Staying ahead in the AI race has been a primary focus for the Trump administration, which unveiled its " AI Action Plan" last month. The 28-page plan calls for a light-touch approach to AI regulation compared to Trump's predecessor, President Joe Biden. In January, Chinese AI startup DeepSeek shocked the world with its high-performing but relatively cheap AI models. Trump said he viewed DeepSeek's accomplishment "as a positive, as an asset" for America. "The release of DeepSeek, AI from a Chinese company, should be a wake-up call for our industries that we need to be laser-focused on competing to win," Trump told GOP lawmakers in January.
CBS News
16 minutes ago
- CBS News
Perseids meteor shower will peak this week. But will the moon ruin it for viewers?
The Perseids meteor shower — considered one of the best shows in the sky — is set to peak this week. But the peak for fireballs shooting through the night sky coincides this year with a bright moon that is expected to negatively impact visibility for eager viewers. The Perseids peak in 2025 is Aug. 12-13, specifically early Wednesday for those in North America. At that time, the moon will be 84% full, according to the American Meteor Society. "In 2025, the waning gibbous moon will severely compromise this shower at the time of maximum activity," the organization says. "Such conditions will reduce activity by at least 75 percent as only the brighter meteors will be visible." Viewers this year can expect to see between 10-20 Perseids each hour, as opposed to 50 Perseids per hour under darker conditions, it says. "The strength of each Perseid display varies year to year, mainly due to lunar conditions," writes Robert Lunsford with the American Meteor Society. "If a bright moon is above the horizon during the night of maximum activity, then the display will be reduced. Most of the Perseid meteors are faint and bright moonlight will make it difficult to view." The Perseids meteor shower has been ongoing for several weeks. It started in mid-July and will continue until Aug. 23. A planetarium program coordinator at a museum in St. Paul, Minnesota, is advising people to instead go out a week or so past the peak when the moon isn't so bright. The Perseids "are an incredible meteor shower," Thaddeus LaCoursiere, of the Bell Museum, told The Associated Press. NASA says the best time to view the Perseids is early in the morning, before the sun comes up, in the Northern Hemisphere. However, meteors sometimes can be seen as early as 10 p.m. When looking at the Perseids, they appear to come from the constellation Perseus, which is why this meteor shower has its name. But the meteors don't originate from the constellation; they are space debris left by a comet. That debris interacts with Earth's atmosphere, disintegrating and resulting in colorful lines in the sky, according to NASA and the American Meteor Society. "The pieces of space debris that interact with our atmosphere to create the Perseids originate from comet 109P/Swift-Tuttle," which last visited the inner solar system in 1992, NASA says. During peak, Tuesday night and Wednesday morning, the Earth will pass closest to the core orbit of comet 109P/Swift-Tuttle, Lunsford writes. "To view the Perseids successfully, it is suggested you watch from a safe rural area that is as dark as possible," he says. "The more stars you can see, the more meteors will also be visible."
